Radiation Dosimetry and Biodistribution of the TSPO Ligand 11C-DPA-713 in Humans

Journal of Nuclear Medicine

Jennifer M. Coughlin¹  Martin G. Pomper¹  Crystal C. Watkins¹  Michael Kassiou¹  Kenneth L. Gage¹  Christopher J. Endres¹ 

关键词: radiotracer tissue kinetics;    dosimetry;    microglia;    PET/CT;    translocator protein;   

DOI  :  10.2967/jnumed.111.094565

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Whole-body PET/CT was used to characterize the radiation dosimetry of 11C-DPA-713, a specific PET ligand for the assessment of translocator protein. Methods: Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of 11C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time–activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding. Results: The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 × 10−2 mSv/MBq (7.43 × 10−2 rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for 11C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi). Conclusion: 11C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other 11C-labeled PET tracers.

【 授权许可】

Unknown